journal of men's health
Volume 5 , Pages S18-S20 , September 2008

Testosterone and cardiovascular disease

References 

  1. Stamler J, Stamler R, Riedlinger WF, Algera G, Roberts RH. Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975. Jama. 1976;235(21):2299–2306
  2. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8–13
  3. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60(2): 427-39.
  4. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174(3):827–834
  5. Nettleship JE, Jones TH, Channer KS, Jones RD. Testosterone replacement therapy attenuates fatty streak formation and improves high density lipoprotein cholesterol in the Tfm mouse; an effect which is independent of the classical nuclear androgen receptor. Circulation. 2007;116:2427–2434
  6. Muller M, van den Beld AW, van der Schouw YT, Grobee DE, Lamberts SW. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–2079
  7. Makinen J, Jarvisalo MJ, Pollanen P, Pereentupa A, Irjala K, Koskenvuo M, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005;45(10):1603–1608
  8. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–3639
  9. English KM, Mandour O, Steeds RP, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21(11):890–894
  10. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–1665
  11. Araujo A, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med. 2007;167:1252–1260
  12. Malkin CJ, Jones RD, Jones TH, Channer KS. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006;111(4):265–274
  13. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol. 1942;2:325–328
  14. Walker TC. The use of testosterone propionate and estrogenic substance in the treatment of essential hypertension, angina pectoris and peripheral vascular disease. Journal of Clinical Endocrinology. 1942;2:560–568
  15. Sigler LHTJ. Treatment of angina pectoris by testosterone propionate. New York State Journal of Medicine. 1943;43:1424–1428
  16. Lesser MA. Testosterone propionate therapy in one hundred cases of angina pectoris. Journal of Clinical Endocrinology. 1946;6:549–557
  17. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977;39(11):1217–1222
  18. Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl). 1993;106(6):415–418
  19. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100(16):1690–1696
  20. English KM, Steeds RP, Diver MJ, Jones TH, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911
  21. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99(13):1666–1670
  22. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, et al. Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J. 2002;143(2):249–256
  23. Malkin CJ, Pugh PJ, Morris PD, Hall J, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90(8):871–876
  24. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003;24(10):909–915
  25. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004;90(4):446–447
  26. Malkin CJ, Pugh PJ, West JN, van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27(1):57–64
  27. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, et al. Anabolic deficiency in men with chronic heart failure; prevalence and detrimental impact on survival. Circulation. 2006;114:1829–1837
  28. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–3318

PII: S1875-6867(08)00071-7

doi: 10.1016/j.jomh.2008.03.010

journal of men's health
Volume 5 , Pages S18-S20 , September 2008

Article Tools